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Abstract
CD5-positive marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) of the lung is very
rare. An 82-year-old Japanese woman was found to have an abnormal lung shadow on chest X-ray photography,
and was admitted to our hospital. Imaging modalities including X-ray photography, computed tomography, and
magnetic resonance imaging showed a small (2 × 1 × 1 cm) opacity of the right upper lobe. Transbronchial lung
biopsy was performed. It showed severe proliferation of small lymphocytes. The small lymphocytes were
centrocytes-like, and minor plasma cell differentiation was recognized. Lymphoepithelial lesions were scattered.
Immunohistochemically, the tumor cells were positive for CD5, CD20, CD43, CD45, CD79a, bcl-2, and -chain, but
negative for CD2, CD3, CD10, CD21, CD23, CD35, CD45RO, CD56, IgA, IgG, IgM, IgD, l-chain, TdT, and cyclin D1.
The Ki-67 labeling was 10%. CD3-positive and CD45RO-positive inflammatory T-cells were scattered in small
amount. The pathological diagnosis was CD5-positive marginal zone B-cell lymphoma of the mucosa-associated
lymphoid tissue (MALT) of the lung. The patient was treated with chemotherapy (CHOP: cyclophosphamide,
hydroxydaunorbicin, vincristine, and predonisone), and the lung tumor disappeared. The patient is now free of the
lymphoma 10 years after the first manifestation.
Virtual slides: The virtual slide(s) for this article can be found here:
http://www.diagnosticpathology.diagnomx.eu/vs/1541653085652296
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Introduction
Malignant lymphoma of the lung is very rare [1].
Although any types of malignant lymphomas can occur
in the lung, approximately 70-90% of the pulmonary
lymphoma is marginal zone B-cell lymphoma of the
mucosa-associated lymphoid tissue (MALT) of the lung
[1]. Pulmonary lymphomas accounted for only 0.5% of
all pulmonary neoplasms [1]. Patients with marginal
zone B-cell lymphoma of the mucosa-associated lym-
phoid tissue (MALT) (abbreviated hereafter as MALT
lymphoma) of the lung tend to be in their fifth, sixth, or
seventh decades, with a slight male preponderance [1].
Etiologically, pulmonary MALT lymphoma is thought to
arise in acquired MALT secondary to inflammatory or
autoimmune process. The prognosis of pulmonary
MALT lymphoma is relatively good when surgical resec-
tion is possible, while it may be worse in surgically-
unresectable cases [1]. The 5-year survival of pulmonary
MALT lymphoma is 84-94% [1]. Pulmonary MALT lym-
phoma progresses into diffuse large B-cell lymphoma in
a small percentage, as is the case with MALT lymphoma
of other organs. Other relatively common lymphomas
and related diseases of the lung are diffuse large B-cell
lymphoma, lymphomatoid granulomatosis, and Langer-
hans cell histiocytosis [1]. Histopathologically, pulmon-
ary MALT lymphoma is an extranodal marginal zone
lymphoma comprising morphologically of heterogeneous
small B-cells, monocytoid cells, small lymphocytes, and
scattered immunoblasts-like and centroblasts-like cells.
There is a plasma cell differentiation in a proportion of
cases. The neoplastic cells typically infiltrate into the
bronchial mucosal epithelial cells, creating lymphoe-
pithelial lesions [1]. Correspondence: piyo0111jp@yahoo.co.jp
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However, there are a few reports of CD5-positive
MALT lymphoma of the lung and other organs [3-13].
The CD5 positivity in MALT lymphoma made the diag-
nosis difficult, and many differential diagnoses should be
considered. The significance, mechanism, and biological
behaviors of CD5-positive MALT lymphoma are
unknown [3-13]. The author herein reports the case of a
CD5-positive pulmonary MALT lymphoma with good
prognosis.
Case report
An 82-year-old Japanese woman was found to have
abnormal lung shadow on chest X-ray photography at a
private hospital. She was referred to our hospital for
scrutiny. Imaging modalities including X-ray photogra-
phy, computed tomography and magnetic resonance
i m a g i n gs h o w e das m a l l( 2×1×1c m )o p a c i t yo fr i g h t
upper lobe. Abnormal blood laboratory data included
mild leukocytosis (9.5 × 10
9 /L; normal 3.5-9.0 × 10
9/L),
anemia (367 x10
10 /L; normal, 370-480 × 10
10/L; hemo-
globin 9.5 g/dl, normal 11 g/dl-16 g/dl), decreased total
protein (63 g/L; normal 65-92 g/L), low zinc turbidity
test (2.3 U; normal 4.0-12.0 U), and increased blood uria
nitrogen (2.4 μmol/L; normal 2.9-8.9 μmol/L). The
white blood cell compartment was as follows: basophils
1%, band neutrophils 2% (low), segmented neutrophils
84% (high), and lymphocytes 11% (low). Eosinophils and
precursor cells were not recognized. Other data were
normal. There was no M-protein. No hyper-gamma-glo-
bulinemia was noted. Examination of serum immuno-
globulin components was not performed.
Transbronchial lung biopsy (TBLB) was performed. The
TBLB specimens consisted of several fragments. They
are fragments of the proliferated lymphocytes (Figure
1A). The TBLB showed severe proliferation of small
lymphocytes with scattered small centroblast-like cells
(Figure 1B). The lymphocytes were centrocytes-like, and
minor plasma cell differentiation was recognized (Figure
1B). Lymphoepithelial lesions were scattered (Figure 1B),
and they were highlighted by cytokeratin immunostain-
ing (Figure 1C). No follicular structures were found. No
findings of Burkitt lymphoma were recognized.
An immunohistochemical study was performed with
the use of Dako’s EnVision method (Dako Corp, Carpin-
teria, CA), as previously described [14-16].
Each immunostaing was pretreated by microwave
oven heating for 10 minutes. The antibodies, clones, and
dilution used were as follows: CD2 (Dako, MT910,
1:100), CD3 (Dako, F7.2.38, 1:25), CD5 (Dako, CD5/54/
F 6 ,1 : 5 0 ) ,C D 1 0( N o v o c a s t r a ,N e wC a s t l eU p o nT y n e ,
UK, NCL-CD10-270, 1:100), CD20 (Dako, L26, 1:100),
CD21 (Dako, 1F8, 1:25), CD23 (Dako, MHM-6, predi-
luted), CD35 (Dako, Ber-MAC-DRC, 1:25), CD43 (Dako,
DF-T1, prediluted), CD45 (Dako, LCA, 1:100), CD45RO
(Dako, UCHL-1, 1:100), CD56 (Novocastra, NCL-CD56-
1B6, 1:100,), CD79a (Dako, JCB117, 1:200), bcl-2 (Dako,
124, 1:150), cyclin D1 (Dako, DCS-6), TdT (Dako,
A3524, 1:100), IgA (Dako, 6E2C1, 1:100), IgG (Dako,
A57H, 1:150), IgM (Dako, polyclonal, 1:50), -chain
(Dako, polyclonal, 1:200), l-chain (Dako, polyclonal,
1:100), and Ki-67 (MBL Japan, MIB-1, 1:200)
Immunohistochemically, the tumor cells were positive
for CD5 (Figure 2A), CD20 (Figure 2B), CD43, CD45,
CD79a,b c l - 2 ,a n d-chain (Figure 2C), but negative for
l-chain (Figure 2D), CD2, CD3 (Figure 2E), CD10,
CD21, CD23, CD35, CD45RO, CD56, TdT, IgA, IgG,
IgM, IgD, and cyclin D1. The Ki-67 labeling was 10%.
CD3-positive and CD45RO-positive inflammatory T-
cells were scattered in a small amount. Light chains
immunostainings showed light chain restriction (Figures
2C and 2D) and a small number of plasma cells (Figure
2C). Methylgreenpyronine staining showed a small num-
ber of plasma cells. The pathological diagnosis was
CD5-positive MALT lymphoma. After the TBLB, a bone
marrow biopsy was performed. It showed normocellular
marrow with normal erythroid, granulocytoid and mega-
karyocytic maturation. No atypical cells were identified
in the bone marrow.
The patient rejected surgical procedure because of
very old age, and was treated with chemotherapy
(CHOP: cyclophosphamide, hydroxydaunorbicin, vincris-
tine, and predonisone), and the lung tumor disappeared.
The patient is now free of MALT lymphoma 10 years
after the first manifestation.
Discussion
The present lung tumor was composed of B cells. The
lymphoid cells were small. Plasma cell differentiation
was seen in a slight degree. Lymphoepithelial lesions
were scattered. -chain was positive but l-chain was
negative, confirming the light chain restriction and a
tumor cell monoclonality. Therefore, the present case
was low-grade B-cell lymphoma. The low grade and
intermediate grade B-cell lymphoma consists of small
lymphocytic lymphoma (low grade), lymphoplasmcytic
lymphoma (low grade), follicular lymphoma (low grade),
MALT lymphoma (low grade), and mantle cell lym-
phoma (intermediate grade). The present case is not
small lymphocytic lymphoma/chronic leukocytic leuke-
mia, which shows monotonous proliferation of mature
small lymphocytes and free from centrocyte-like cells
and lymphoepithelal lesions. Immunohistochemically,
small lymphocytic lymphoma expresses IgM/IgD, CD20,
CD22, CD5, CD19, CD79a, CD23, CD43 and CD11c.
CD10 is negative. In the present case, IgM/D and CD23
were negative, supporting that the current case is not
small lymphocytic lymphoma. The current case is not
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were scant in number and there was no M-protein.
Negative immunoglobulins except for -chain in tumor
cells are also against the diagnosis of lymphoplasmacytic
lymphoma. The presence of centrocyte-like cells, lym-
phoepithelial lesions, and plasmacytoid differentiation is
characteristic features of MALT lymphoma. The clinical
features are also against lymphoplasmacytic lymphoma,
which frequently shows extrapulmonary and marrow
involvements and shows M-protein and hyper-gamma-
globulinemia. Positive -chain in the current case may
be due to the plasmacytoid differentiation of MALT
lymphoma. The plasma cells in the present case are due
to plasmacytoid differentiation of the MALT lymphoma,
which is a characteristic feature of MALT lymphoma
[2]. The present tumor is not follicular lymphoma
because no follicular structures were recognized. The
positive reaction for CD5 and negative reaction for
CD10 and CD35 also exclude the possibility of follicular
lymphoma, in which CD5 is negative and CD10 and
CD35 (a marker of follicular dendritic cells) are positive.
Although CD10 is infrequently positive in follicular
lymphoma, the morphology, immunohistochemistry, the
presence of plasmacytoid cells and lymphoepithelial
lesions are in favor of MALT lymphoma rather than folli-
cular lymphoma. The present tumor is not mantle cell
lymphoma, because of negative cyclin D1 which is almost
always positive in mantle cell lymphoma [17]. The differ-
ential diagnosis of CD5-positive MALT lymphoma and
cyclin D1-negative mantle cell lymphoma is very difficult.
Mantle cell lymphoma is composed of monotonous pro-
liferation of small cells of mantle zone. In mantle cell
lymphoma, no centrocyte-like cells, plasma cell differen-
tiation, or lymphoepithelial lesions are seen. In the pre-
sent case, the histologies are those of MALT lymphoma.
In addition, the good prognosis of the present case is in
favor of MALT lymphoma rather than mantle cell lym-
phoma, which shows poor prognosis. Therefore, the
author diagnosed this tumor as MALT lymphoma. A
genetic study of t(11:18)(q21:q21) (MALT lymphoma)
and t(11:14)(q13:q31)(mantle cell lymphoma) are
required for the distinction. In the present case, no
genetic study was performed. The present case is differ-
ent from benign lymphoproliferative diseases of lung,
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Figure 1 Histological features. A: Diffuse atypical lymphoid cell proliferation is seen. HE, ×100. B: The atypical cells are small lymphoid cells
with hyperchromatic nuclei. Lymphoepithelial lesions are seen. HE, × 400. C: The lymphoepithelial lesions are clearly accentuated by cytokeratin
immunostaining. AE1/3 immunostaining, ×200.
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pneumonia, and nodular lymphoid hyperplasia [18]
because the present case shows neoplastic characteristics
which were demonstrated by B-cell monoclonality and
light chain restriction (light chain monoclonality). Thus,
the neoplastic characteristics of the present case rule out
these reactive lymphoproliferative conditions [18]. These
findings are compatible with a diagnosis of MALT lym-
phoma of the lung.
Immunohistochemically, the low and intermediate
grade B-cell lymphomas show the following immuno-
phenotypes: follicular lymphoma, CD5-, CD10 +, CD23
-, CD43 -, cyclin D1 -; MALT lymphoma, CD5-, CD10-,
CD23-, CD43+/-, cyclin D1 -; mantle cell lymphoma,
CD5+, CD10-, CD23-, CD43 +/-, cyclin D1 + [2]. The
present case was as follows: CD5+, CD10-, CD43+,
cyclin D1 -. The immunoprofile is compatible with to
MALT lymphoma. The histological features of the
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Figure 2 Immunohistochemical features. The tumor cells are positive for CD5 (A), CD20 (B), and -chain (C). l-chain was negative (D). A, B, C:
×200. D, x400. The tumor cells were negative for CD3 (E). A small amount of CD3-positive inflammatory cells are seen (E). E: ×200.
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plasma cell differentiation, are also those of MALT lym-
phoma [2].
The CD5 positivity of the present MALT lymphoma is
unique. CD5-positive MALT lymphoma has been rarely
reported [3-13]. The brief clinicopathological findings of
the present case and reported cases are summarized in
Table 1. Ballesteros et al [3] mentioned that CD5-posi-
tive MALT lymphoma tended to show wide spread dis-
ease in the literature, and presented three cases of CD5-
positive MALT lymphoma and stated that CD5-positive
MALT lymphomas were localized tumors. The sites of
the lymphoma were uterus, lymph nodes, lung, and con-
junctiva [3]. Tasaki et al [4] reported two cases of CD5-
positive MALT lymphoma of ocular adnexa. They
stressed the differential diagnosis between CD5-positive
MALT lymphoma and mantle cell lymphoma [4].
Hisabe et al [5] reported a case of CD5-positive MALT
lymphoma of the rectum which regressed after adminis-
tration of antibiotics. Sundeen et al [6] mentioned 11
cases of CD5-positive B-cell small lymphocytic malig-
nancies of various organs. Mikolaenko and Listinsky [7]
reported a case of CD5-positive MALT lymphoma with
systemic involvement and Waldenstrom syndrome.
Ferry et al [8] reported 3 cases of CD5-positive MALT
lymphoma of orbit and tongue with recurrence. Kubota
et al [9] reported 3 case of CD5-positive MALT lym-
phoma of orbit with autoantibodies. Tsukamoto et al
[10] reported a case of cutaneous CD5-positive MALT
lymphoma resembling the plasma cell variant of Castle-
man’s disease. Wenzel et al [11] reported a case of
CD5-positive MALT lymphoma of the conjunctiva with
Table 1 The present case and reported cases of CD5-positive MALT lympoma
Case Age Sex Site Morphology LEL Immunophenotype Reporters Ref.
No. (yr)
1 72 F Uterus MALT + CD3 -, CD5 +, CD20 + Ballesteros
et al
[3]
1 72 F Lymph nodes MALT + CD3 -, CD5 +, CD10 -, CD11c +, CD20+, CD23 - Ballesteros
et al
[3]
2 56 M Lung MALT + CD3-, CD5 +, CD10+, CD20+, Ballestetos
et al
[3]
3 70 F Conjunctive MALT + CD3-, CD5+, CD10-, CD11c-, CD20 + Ballestetos
et al
[3]
4 57 F Eyelid MALT + CD3-, CD5+, CD10-, CD20+, CD23 - CD79a+, cyclin D1-, bcl-2+ Tasaki et al [4]
5 67 M Orbit MALT - CD3-, CD5+, CD10-, CD20+, CD23 - CD79a+, cyclin D1-, bcl-2+, chain
+
Tasaki et al [4]
6 70 F Rectum MALT ND CD5+, CD10-, CD20+, CD45RO-, bcl-2+ Hisabe et al [5]
7 75 M Systemic MALT + CD5+, CD10-, CD19+, CD20+, CD11C-FMC7+, IgMl+ Mikolaenko
et al
[7]
8 77 M Orbit MALT + CD5+, CD10-, CD20+, CD22 +CD23-, CD43-, IgMl+, Cyclin D1-, leu7 + Ferry et al [8]
9 44 M Orbit, blood
Marrow, lymph
nodes
MALT + CD5+, CD10-, CD20 + CD22+, CD23-, CD43+, IgM+, leu8+, cyclin D1- Ferry et al [8]
10 62 F Tongue MALT + CD5+, CD10-, CD20+, CD23+, CD43+sIg-, cyclin D1- Ferry et al [8]
11 82 ND Orbit MALT ND CD3-, CD5+, CD20+, CD23-, cyclinD1- Kubota et
al
[9]
12 70 ND Orbit MALT ND CD3-, CD5+, CD20+, CD23-, cyclinD1- Kubota et
al
[9]
13 84 ND Orbit MALT ND CD3-, CD5+, CD20+, CD23-, cyclinD1- Kubota et
al
[9]
14 57 F Skin MALT ND CD3-, CD5+, CD10-, CD20+, CD21-, CD23-, CD43+, bcl-2+, BSAP+, IgG
+
Tsukamoto
et al
[10]
15 73 M Conjunctiva MALT ND CD2-, CD3-, CD5+, CD10-, CD20+, CD23-, CD79a+, Cyclin D1- Wenzel et
al
[11]
16 87 F breast Lymph
nodes
MALT + CD3-, CD5+, CD10-, CD21-, CD23-, bcl-2+chain-,lchain+, bcl-6-.
cyclinD1-
Batstone et
al
[12]
17 79 M Conjunctiva MALT - CD5+, CD20+, CD23-, CD30-, Heuring et
al
[13]
18 82 F Lung MALT + CD2-, CD3-, CD5+, CD10-, CD20+, CD23-, CD43+, CD45+, CD45RO-,
CD56-, CD79abcl-2+,chain+,lchain-, IgA-, IgG-, IgM-, TdT-, cyclinD1-
Terada
Present
case
ND: not described. LEL: Lymphoepithelial lesion.
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stone et al [12] reported a case of CD5-positive MALT
lymphoma of the breast and lymph nodes with genetic
analyses. Heuring et al [13] reported a case of conjuncti-
val CD5-positive MALT lymphoma. Because the num-
ber of cases of CD5-positive MALT lymphoma is very
small, its biological characteristics are unknown.
The MALT lymphoma of the present case disappeared
after CHOP chemotherapy, and has not recurred for 10
years. Surgical procedure was not done because the
patient rejected the surgical operation. The prognosis of
pulmonary MALT lymphoma is not worse. The five
year survival is 84-94% [1]. Kurtin et al. [19] described
that lymphoma-specific survival of pulmonary MALT
lymphoma was 71.7% at 10 years. Borie et al [20]
described that the 5 years survival was 90% and 10 years
survival was 72% in pulmonary MALT lymphoma. The
present patient is alive free from tumor 10 years after
the CHOP medical treatment without surgical
intervention.
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